| Menopause |
1 |
1 |
| Hormonal Therapy |
0 |
0.99 |
| Thromboembolism |
0 |
0.26 |
| Estrogen |
0 |
0.25 |
| Cardiovascular Risk Management |
0 |
0.21 |
| Coronary Artery Disease (CAD) |
0 |
0.19 |
| Cerebrovascular Accident |
0 |
0.14 |
| Bone |
0 |
0.13 |
| Heart |
0 |
0.13 |
| Fractures |
0 |
0.12 |
| Osteoporosis |
0 |
0.11 |
| Breast |
0 |
0.09 |
| Insurance |
0 |
0.09 |
| Quality of Life |
0 |
0.09 |
| Transdermal |
0 |
0.09 |
| Vagina |
0 |
0.09 |
| Venous Thromboembolism (VTE) |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.08 |
| Endometrial Cancer |
0 |
0.06 |
| Genomic Medicine |
0 |
0.06 |
| Pulmonary Embolism |
0 |
0.06 |
| Cancer |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Dementia |
0 |
0.04 |
| Embolism |
0 |
0.04 |
| Genetics |
0 |
0.04 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Hypogonadism |
0 |
0.04 |
| Infertility Female |
0 |
0.04 |
| Ovarian Insufficiency |
0 |
0.04 |
| Postmenopause |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Tissue |
0 |
0.04 |